Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
18.49 USD | +1.59% | +0.43% | -40.95% |
Financials (USD)
Sales 2024 * | 968M | Sales 2025 * | 1.1B | Capitalization | 3.05B |
---|---|---|---|---|---|
Net income 2024 * | 112M | Net income 2025 * | 219M | EV / Sales 2024 * | 2.52 x |
Net cash position 2024 * | 606M | Net cash position 2025 * | 863M | EV / Sales 2025 * | 1.99 x |
P/E ratio 2024 * |
28.2
x | P/E ratio 2025 * |
14.3
x | Employees | 598 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.48% |
Latest transcript on ACADIA Pharmaceuticals Inc.
1 day | +1.59% | ||
1 week | +0.43% | ||
Current month | -20.44% | ||
1 month | -22.13% | ||
3 months | -41.09% | ||
6 months | -14.12% | ||
Current year | -40.95% |
Managers | Title | Age | Since |
---|---|---|---|
Stephen Davis
CEO | Chief Executive Officer | 63 | 14-07-14 |
Mark Schneyer
DFI | Director of Finance/CFO | 50 | 20-05-27 |
Sanjeev Pathak
CTO | Chief Tech/Sci/R&D Officer | - | 21-02-28 |
Members of the board | Title | Age | Since |
---|---|---|---|
Julian Baker
BRD | Director/Board Member | 57 | 15-12-10 |
Edmund Harrigan
BRD | Director/Board Member | 71 | 15-11-24 |
Stephen Davis
CEO | Chief Executive Officer | 63 | 14-07-14 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
3.73% | 1 M€ | -.--% | - | |
1.24% | 17 M€ | -0.46% | ||
0.26% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 18.49 | +1.59% | 1,531,606 |
24-03-27 | 18.2 | +2.30% | 1,701,367 |
24-03-26 | 17.79 | -0.28% | 1,445,409 |
24-03-25 | 17.84 | -0.61% | 1,845,162 |
24-03-22 | 17.95 | -2.50% | 1,480,951 |
Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-40.95% | 3.05B | |
+9.30% | 46.03B | |
+52.73% | 44.55B | |
+7.15% | 40.8B | |
-8.78% | 28.25B | |
+18.68% | 27.71B | |
-21.92% | 18.82B | |
+14.62% | 13.91B | |
+31.85% | 12.43B | |
+4.47% | 10.81B |